Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • M&A / Deals
  • Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs
  • M&A / Deals

Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs

BioSpace

With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.

M&A / DealsNeuroscienceRead full story

pharminent April 21, 2026 (Last updated: April 21, 2026)

BioSpace

With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.

M&A / DealsNeuroscienceRead full story

Post navigation

Previous: Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer
Next: BioAge says early data suggest ‘best-in-class’ potential for inflammation drug

Related Stories

  • M&A / Deals

Solstice Oncology secures $225m to drive porustobart’s development for cancer

pharminent September 10, 2026
  • M&A / Deals

UK’s Claret Capital raises 575m for European biotechs

pharminent September 7, 2026
  • M&A / Deals

GSK wagers up to $1.3B on a different kind of cancer drug

pharminent September 3, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.